Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference
TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined...
Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy
TAIPEI and SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological...
Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today
TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr. Benny T. Hu. The company delivered...
Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD)....